This study shows that KL-50, a novel cancer drug, effectively kills MGMT-deficient tumors—including colon cancer, melanoma, and lung cancer, while overcoming temozolomide resistance.
This study shows that liquid biopsy—blood-based tumor DNA testing—reveals widespread treatment-resistance mutations across 12,827 patients with metastatic breast cancer.